Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashraf Osman

Thoracic Surgery (Cardiothoracic Vascular Surgery) Las Vegas, NV Medical Doctor

NPI 1063453918 CMS profile 230024

4445 S Eastern Ave, Las Vegas, NV 89119

Open in the dashboard

General payments

$53,635

451 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashraf Osman of Las Vegas, NV is reported in the CMS Open Payments database as having received $53,635 across 451 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,997 44
2024 General $18,488 85
2023 General $10,583 78
2022 General $6,341 68
2021 General $4,343 55
2020 General $3,150 39
2019 General $7,733 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashraf Osman
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Ashraf Osman were reported at $2,997. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Ashraf Osman Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $7,733 $886 $178–$3,167 $163
2020 $3,150 $341 $108–$1,605 $114
2021 $4,343 $453 $125–$1,886 $132
2022 $6,341 $695 $180–$2,566 $149
2023 $10,583 $745 $205–$2,662 $160
2024 $18,488 $799 $214–$2,967 $164
2025 $2,997 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $9,446 40 payments
  2. Smith+Nephew, Inc. $9,272 17 payments
  3. Medtronic, Inc. $7,394 84 payments
  4. Edwards Lifesciences Corporation $4,688 39 payments
  5. Medtronic Vascular, Inc. $4,646 45 payments
  6. Abiomed $3,978 44 payments
  7. W. L. Gore & Associates, Inc. $3,353 41 payments
  8. Abbott Laboratories $2,398 32 payments
  9. Atricure, Inc. $2,259 18 payments
  10. Penumbra, Inc. $1,112 13 payments
  11. Other $5,088 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $25,349 384 payments
  2. Travel and Lodging $15,067 63 payments
  3. Consulting Fee $7,719 1 payment
  4. Education $5,500 3 payments
Products named General payments · program years 2019–2025
  1. PICO $9,272 17 payments
  2. DAVINCI XI $5,500 3 payments
  3. Da Vinci Surgical System $3,946 37 payments
  4. Impella $3,682 41 payments
  5. CoreValve Evolut $3,551 26 payments
  6. ENDURANT IIS $3,359 31 payments
  7. COREVALVE EVOLUT R $2,188 21 payments
  8. GORE TAG Thoracic Endoprosthesis $2,155 15 payments
  9. INSPIRIS RESILIA aortic valve $1,808 7 payments
  10. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $1,009 1 payment
  11. Other $17,018 244 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$114,620

Medicare's payments for the services billed

Medicare patients

138

Average age 72

Services billed

748

52 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Diabetes 57%
Heart failure 54%
COPD 51%
Atrial fibrillation 50%
Chronic kidney disease 49%
Arthritis 45%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record